Mehmet Ergisi
Overview
Explore the profile of Mehmet Ergisi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
35
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ergisi M, Ooi B, Salim O, Papalois V
Transplant Rev (Orlando)
. 2024 Mar;
38(2):100843.
PMID: 38538506
No abstract available.
2.
Ergisi M, Ooi B, Salim O, Papalois V
Transplant Rev (Orlando)
. 2024 Mar;
38(2):100837.
PMID: 38430887
Post-transplant lymphoproliferative disorders (PTLD) is a devastating complication of kidney transplantation with an insidious presentation and potential to disseminate aggressively. This review delineates the risk factors, prognostic indexes, screening, current...
3.
Gokani S, Kumaresan K, Adari S, Ergisi M, Oludeye O, Jegatheeswaran L, et al.
J Clin Med
. 2024 Jan;
13(2).
PMID: 38256532
Paranasal sinus mucocoeles can be secondary to chronic rhinosinusitis and can result in intra-orbital and intra-cranial complications requiring surgical management. The natural history of conservatively managed mucocoeles is not well...
4.
Ergisi M, Law A, Chaudhari N, Tsatsari S, Lawson K, Jenner C
Front Pain Res (Lausanne)
. 2023 Jul;
4:1159268.
PMID: 37465763
Vulvodynia is a leading cause of dyspareunia in premenopausal women, causing considerable morbidity and sexual dysfunction. A multimodal approach is used to treat vulvodynia. Alongside psychosocial interventions and physiotherapy, pharmacological...
5.
Ergisi M, Erridge S, Harris M, Kawka M, Nimalan D, Salazar O, et al.
Cannabis Cannabinoid Res
. 2022 Jan;
8(3):557-566.
PMID: 35073160
There is a growing body of literature supporting the efficacy of cannabis-based medicinal products (CBMPs). Despite an increase in prescribing globally, there is a paucity of high-quality clinical data on...
6.
Nimalan D, Kawka M, Erridge S, Ergisi M, Harris M, Salazar O, et al.
J Cannabis Res
. 2022 Jan;
4(1):3.
PMID: 34980282
Introduction: Palliative care aims to improve quality of life through optimal symptom control and pain management. Cannabis-based medicinal products (CBMPs) have a proven role in the treatment of chemotherapy-induced nausea...
7.
Harris M, Erridge S, Ergisi M, Nimalan D, Kawka M, Salazar O, et al.
Expert Rev Clin Pharmacol
. 2021 Dec;
15(4):473-485.
PMID: 34937477
Objectives: To explore pain-specific, general health-related quality of life (HRQoL), and safety outcomes of chronic pain patients prescribed cannabis-based medicinal products (CBMPs). Methods: A case series was performed using patients...
8.
Ergisi M, Erridge S, Harris M, Kawka M, Nimalan D, Salazar O, et al.
Expert Rev Clin Pharmacol
. 2021 Dec;
15(4):487-495.
PMID: 34937473
Objectives: Anxiety disorders are one of the most common reasons for seeking treatment with cannabis-based medicinal products (CBMPs). Current pharmacological treatments are variable in efficacy and the endocannabinoid system has...